Minimal residual disease in breast cancer: In Blood Veritas

Clinical Cancer Research

Volumn 20, Issue 10, 2014, Pages 2505-2507

  Siravegna, Giulia ^a,b   Bardelli, Alberto ^a,b,c  

^a UNIVERSITY OF TURIN   (Italy)

^b IRCCS   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE;

ARTICLE; BLOOD CHEMISTRY; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; DNA FRAGMENTATION; DROPLET DIGITAL POLYMERASE CHAIN REACTION; EARLY DIAGNOSIS; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; MINIMAL RESIDUAL DISEASE; NEXT GENERATION SEQUENCING; ONCOGENE; PIK3CA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; BLOOD; BREAST NEOPLASMS; FEMALE; GENETICS;

BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; HUMANS;

EID: 84901036171     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0370     Document Type: Article

References (13)

1. Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky D, et al. Detection of cancer DNA in plasma of early stage breast cancer patients. Clin Cancer Res 2014;20:2643-50.
2. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early-And late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
4. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006;94:455-9.
5. Aung KL, Board RE, Ellison G, Donald E, Ward T, Clack G, et al. Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J 2010;4: 11-21.
6. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, et al. Development of figized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2010;2:20ra14.
7. Baker M. Digital PCR hits his stride. Nat Methods 2012;9:541-4.
8. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14:985-90.
9. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
10. Rosen PR, Groshen S, Saigo PE, Kinne DW, Hellman S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989;7:355-66.
11. Gampenrieder SP, Rinnerthaler G, Greil R. Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future. J Oncol 2013;2013:732047.
12. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-42.
13. Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res 2013;19:3276-84.